Sahar Barjesteh van Waalwijk: How can we make such medicines available through insurance coverage?

Sahar Barjesteh van Waalwijk, Pharmacist and Member of National Funder’s Committee for Evaluation of Specialised Medicine & MDx at CZ, posted the following on LinkedIn:

“This is a perfect example of how an investigator-initiated trial can repurpose medicine to improve outcomes for patients with rare cancer types.

The combination of doxorubicin and trabectedin no longer has patent or market exclusivity in the EU, so no regulatory submission is expected. The question remains: how can we make such medicines available through insurance coverage?

Are you curious about how we arrange access to off-label therapies in The Netherlands and how we can stimulate repurposing? Don’t miss the presentation of our research at ESMO – European Society for Medical Oncology, presented by Hans Timmer: 1542MO – Mapping the Scale of Off-Label Use in Oncology: An Important Step in Harmonising Access.

Date: Monday, September 16th

Time: 14:45 – 16:15.”

Doxorubicin–Trabectedin with Trabectedin Maintenance in Leiomyosarcoma

Authors: Patricia Pautier, M.D., Antoine Italiano, M.D., Ph.D., Sophie Piperno-Neumann, M.D., Christine Chevreau, M.D., Nicolas Penel, M.D., Ph.D., Nelly Firmin, M.D., Pascaline Boudou-Rouquette, M.D., Ph.D., François Bertucci, M.D., Ph.D., Valérie Lebrun-Ly, M.D., Isabelle Ray-Coquard, M.D., Ph.D., Elsa Kalbacher, M.D., Emmanuelle Bompas, M.D., Olivier Collard, M.D., Nicolas Isambert, M.D., Ph.D., Cécile Guillemet, M.D., Maria Rios, M.D., Axel Le Cesne, M.D., Corinne Balleyguier, M.D., Ph.D., Baptiste Archambaud, M.S., and Florence Duffaud, M.D., Ph.D., for the French Sarcoma Group.

Source: Sahar Barjesteh van Waalwijk/LinkedIn